Glycolysis: An early marker for vancomycin-specific T-cell activation (2024)
Attributed to:
A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/cea.14423
PubMed Identifier: 38177093
Publication URI: http://europepmc.org/abstract/MED/38177093
Type: Journal Article/Review
Parent Publication: Clinical & Experimental Allergy
Issue: 1
ISSN: 0954-7894